Harmane-d2

Harmane-d2

• UNSPSC Description: Harmane-d2 is the deuterium labeled Harmane. Harmane, a β-Carboline alkaloid (BCA), is a potent neurotoxin that causes severe action tremors and psychiatric manifestations. Harmane shows 1000-fold selectivity for I1-Imidazoline receptor (IC50=30 nM) over α2-adrenoceptor (IC50=18 μM). Harmane is also a potent and selective inhibitor of monoamine oxidase (MAO) (IC50s=0.5 and 5 μM for human MAO A/B, respectively)[1][2][3][4].
• Target Antigen: Adrenergic Receptor; Imidazoline Receptor; Isotope-Labeled Compounds; Monoamine Oxidase
• Type: Isotope-Labeled Compounds
• Related Pathways: GPCR/G Protein;Neuronal Signaling;Others
• Applications: Cancer-programmed cell death
• Field of Research: Cancer; Neurological Disease
• Solubility: 10 mM in DMSO
• Smiles: CC1=NC([2H])=C([2H])C2=C1NC3=C2C=CC=C3
• Molecular Weight: 184.23
• References & Citations: [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.|[2]Louis ED, et, al. Blood harmane concentrations and dietary protein consumption in essential tremor. Neurology. 2005 Aug 9;65(3):391-6.|[3]Musgrave IF, et, al. Harmane produces hypotension following microinjection into the RVLM: possible role of I(1)-imidazoline receptors. Br J Pharmacol. 2000 Mar;129(6):1057-9.|[4]Glover V, et, al. β-Carbolines as selective monoamine oxidase inhibitors:In vivo implications|[5]Umezawa K, et, al. Comutagenic effect of norharman and harman with 2-acetylaminofluorene derivatives. Proc Natl Acad Sci U S A. 1978 Feb;75(2):928-30.
• Shipping Conditions: Room temperature
• Clinical Information: No Development Reported